Evidence from pharmacology and pathophysiology suggests that chemicals with dissimilar mechanisms of action could be of bigger concern in the toxicological risk assessment of chemical mixtures than chemicals with a similar mechanism of action

Regulatory Toxicology and Pharmacology

Volumn 69, Issue 3, 2014, Pages 281-283

  Hadrup, Niels ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Dissimilar mechanism of action; Dose addition; Generalised concentration addition; Independent action; Mixture toxicology; Similar mechanism of action; Toxicological risk assessment; Toxicology

Indexed keywords

AFLATOXIN; ALCOHOL; BERGAMOTTIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG; ENVIRONMENTAL CHEMICAL; HYDROCORTISONE; MINERALOCORTICOID ANTAGONIST; NICOTINE; PROBENECID;

ACUTE HEART INFARCTION; BINDING COMPETITION; CANCER THERAPY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG BINDING SITE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; FOOD DRUG INTERACTION; GENETIC POLYMORPHISM; GRAPEFRUIT JUICE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HUMAN; LIVER METABOLISM; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; TOXICITY TESTING; URINARY EXCRETION; DRUG INTERACTION; EUROPEAN UNION; THEORETICAL MODEL;

DRUG INTERACTIONS; EUROPEAN UNION; HUMANS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 84904048698     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2014.05.007     Document Type: Note

References (30)

1. Backhaus T., Arrhenius A., Blanck H. Toxicity of a mixture of dissimilarly acting substances to natural algal communities: predictive power and limitations of independent action and concentration addition. Environ. Sci. Technol. 2004, 38(23):6363-6370.
2. Backhaus T., Scholze M., Grimme L.H. The single substance and mixture toxicity of quinolones to the bioluminescent bacterium Vibrio fischeri. Aquat. Toxicol. 2000, 49(1-2):49-61.
3. Biondi B. Mechanisms in endocrinology: heart failure and thyroid dysfunction. Eur. J. Endocrinol. 2012, 167(5):609-618. 10.1530/EJE-12-0627.
4. Bliss C.I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 1939, 26(3):585-615.
5. Das K., Arnold E. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. Curr. Opin. Virol. 2013, 3(2):111-118. 10.1016/j.coviro.2013.03.012.
6. EFSA Scientific opinion on the relevance of dissimilar mode of action and its appropriate application for cumulative risk assessment of pesticides residues in food. EFSA J. 2013, 11(12):3472. (European Food Safety Authority (EFSA), Parma, Italy, p. 40).
7. Faust M., Altenburger R., Backhaus T., et al. Joint algal toxicity of 16 dissimilarly acting chemicals is predictable by the concept of independent action. Aquat. Toxicol. 2003, 63(1):43-63.
8. Hadrup N., Taxvig C., Pedersen M., Nellemann C., Hass U., Vinggaard A.M. Concentration addition, independent action and generalized concentration addition models for mixture effect prediction of sex hormone synthesis in vitro. PLoS One 2013, 8(8):e70490. 10.1371/journal.pone.0070490.
9. Haqqani A.A., Tilton J.C. Entry inhibitors and their use in the treatment of HIV-1 infection. Antiviral Res. 2013, 98(2):158-170. 10.1016/j.antiviral.2013.03.017.
10. Hecht S.S. Lung carcinogenesis by tobacco smoke. Int. J. Cancer 2012, 131(12):2724-2732. 10.1002/ijc.27816.
11. Howard G.J., Schlezinger J.J., Hahn M.E., Webster T.F. Generalized concentration addition predicts joint effects of aryl hydrocarbon receptor agonists with partial agonists and competitive antagonists. Environ. Health Perspect. 2010, 118(5):666-672.
12. Howard G.J., Webster T.F. Generalized concentration addition: a method for examining mixtures containing partial agonists. J. Theor. Biol. 2009, 259(3):469-477.
13. Imamura Y., Tsuruya Y., Damme K., et al. 6beta-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. Drug Metab. Dispos. 2014, 42(4):685-694. 10.1124/dmd.113.055475.
14. Loewe S., Muischnek H. Combinated effects. I. Announcement - implements to the problem. Naunyn-Schmiedebergs Arch. Pharmakol. 1926, 114:313-326.
15. Mato A.R., Feldman T., Goy A. Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. Oncologist 2012, 17(5):694-707. 10.1634/theoncologist.2011-0341.
16. McAlpine C.S., Bowes A.J., Werstuck G.H. Diabetes, hyperglycemia and accelerated atherosclerosis: evidence supporting a role for endoplasmic reticulum (ER) stress signaling. Cardiovasc. Hematol. Disord. Drug Targets 2010, 10(2):151-157.
17. Moller S., Henriksen J.H. Cirrhotic cardiomyopathy. J. Hepatol. 2010, 53(1):179-190. 10.1016/j.jhep.2010.02.023.
18. Nielsen, E.N., Boberg, J., Isling, L.K., Kroghsbo, S., Hadrup, N., Bredsdorff, L., Mortensen, A., Larsen, J.C., 2012. Identification of Cumulative Assessment Groups of Pesticides, pp. 1-303. http://www.efsa.europa.eu/en/supporting/doc/269e.pdf.
19. Olmstead A.W., LeBlanc G.A. Toxicity assessment of environmentally relevant pollutant mixtures using a heuristic model. Integr. Environ. Assess. Manage. 2005, 1(2):114-122.
20. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999, 341(10):709-717. 10.1056/NEJM199909023411001.
21. Quashie P.K., Mesplede T., Wainberg M.A. HIV drug resistance and the advent of integrase inhibitors. Curr. Infect. Dis. Rep. 2013, 15(1):85-100. 10.1007/s11908-012-0305-1.
22. Rehm J., Taylor B., Mohapatra S., et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010, 29(4):437-445. 10.1111/j.1465-3362.2009.00153.x.
23. Sica D.A. Interaction of grapefruit juice and calcium channel blockers. Am. J. Hypertens. 2006, 19(7):768-773. 10.1016/j.amjhyper.2005.11.003.
24. Silva E., Rajapakse N., Kortenkamp A. Something from "nothing" - eight weak estrogenic chemicals combined at concentrations below NOECs produce significant mixture effects. Environ. Sci. Technol. 2002, 36(8):1751-1756.
25. Silverberg D.S., Wexler D., Iaina A., Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin. Nephrol. 2006, 26(4):296-306. 10.1016/j.semnephrol.2006.05.006.
26. U.S._Environmental Protection Agency, 2014. Toxic Substances Control Act (TSCA) Chemical Substance Inventory. In: U.S. Environmental Protection Agency. (accessed 11.03.14). http://www.epa.gov/oppt/existingchemicals/pubs/tscainventory/basic.html.
27. Uejima E., Takahashi K., Morisaki T., et al. Microsomal enzyme induction and clinical aggravation of porphyria: the evaluation of human urinary 6beta-hydroxycortisol/cortisol ratio as the index of hepatic CYP3A4 activity. J. Clin. Pharmacol. 2002, 42(12):1374-1379.
28. Wensing A.M., van Maarseveen N.M., Nijhuis M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res. 2010, 85(1):59-74. 10.1016/j.antiviral.2009.10.003.
29. Wild C.P., Gong Y.Y. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis 2010, 31(1):71-82. 10.1093/carcin/bgp264.
30. Worns M.A. Systemic therapy and synergies by combination. Digest. Dis. 2013, 31(1):104-111. 10.1159/000347202.